Skip to main content

InvestmentPitch Media Video Discusses LOVE Pharma’s Signing of Non-Binding LOI to Acquire 100% of Naltrexone Therapeutics Inc., a Pharmaceutical Technology Company with Significant IP Related to the Transdermal Delivery of FDA Approved Naltrexone

Written by Customer Service on . Posted in Public Companies.

VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) — LOVE Pharma (CSE:LUV) (FSE:G1Q0) has signed a non-binding Letter of Intent to acquire 100% of Naltrexone Therapeutics Inc., a pharmaceutical technology company with significant IP related to the transdermal delivery of FDA approved Naltrexone. Naltrexone is an opioid antagonist, primarily used to manage alcohol and or opioid use disorder by reducing cravings and feelings of euphoria associated with substance abuse disorder.

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

LOVE Pharma signs a non-binding LOI to acquire 100% of Naltrexone Therapeutics Inc., a pharmaceutical technology company with significant IP related to the transdermal delivery of FDA approved Naltrexone: LOVE Pharma (CSE:LUV) (FSE:G1Q0) signs a non-binding Letter of Intent to acquire 100% of Naltrexone Therapeutics Inc., a pharmaceutical technology company with significant IP related to the transdermal delivery of FDA approved Naltrexone

For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company. The video is available for viewing on “InvestmentPitch” and on “YouTube”. If these links are not enabled, please visit www.InvestmentPitch.com and enter “Love Pharma” in the search box.

Transdermal delivery of Naltrexone is anticipated to regulate dosage, reduce GI related side effects and improve the patient experience overall. Most importantly, transdermal delivery of Naltrexone may eliminate and or reduce current side effects of the drug such as nausea, which may restrict the growth of the existing Naltrexone market.

Zach Stadnyk, President and CEO, stated: “Love Pharma is very excited to add the Naltrexone Therapeutics transdermal patch IP to our addiction treatment portfolio. Transdermal delivery can provide patients with convenient and safe Naltrexone treatment, providing greater bioavailability, steady absorption and fewer GI related side effects common with oral dosages currently available, the latter of which we believe has the potential to expand the market for Naltrexone.”

The transdermal formulation of a drug can be incorporated within a patch which is then applied to the skin surface of the patient, thereby providing a consistent absorption rate over a pre-determined time as prescribed. The delivery method for transdermal delivery of suitable drugs can be highly flexible and can be designed to release drugs over a varied period of hours from 24 hours to 144 hours or more, as well as over a larger number of days.

The drug addiction treatment market is forecast to surpass US$31 billion by 2027.

Zach Stadnyk, President and CEO, added: “Love Pharma is developing a strong thesis around transdermal drug delivery applications in the addiction space due to the multiple patient centred benefits and the Company’s top tier relationships with biotech laboratories that specialize in fast tracking the development, approvals and launch of transdermal drug delivery systems, opening up new markets and applications for existing FDA approved drugs.”

The total consideration of CDN$2,000,000 is payable in common shares, with closing anticipated within 30 days subject to final due diligence. Further details will be released upon the signing of a definitive agreement.

With a focus on the global sexual Health and Wellness markets, Love Pharma was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

The company is well funded, having recently raised more than $2 million, with its shares currently trading at $0.015.

For more information, please visit the company’s website www.love-pharma.com, contact Zach Stadnyk, CEO, at 604-343-2977 or by email at investors@love-pharma.com.

Disclaimer

The information in this Investmentpitch Media Ltd video is for the viewers information only. Love Pharma has paid a fee not exceeding $2,000 in cash to have its current news release produced in video format. The corporate information is based on information that is publicly available. Any information provided by Investmentpitch Media Ltd., through its media services is not to be construed as a recommendation or suggestion or offer to buy or sell securities but is provided solely as an informational media service. Investmentpitch Media Ltd makes no warranties or undertakings as to the accuracy or completeness of this information. All due diligence should be done by the viewer or their financial advisor. Investing in securities is speculative and carries risk.

About InvestmentPitch Media

InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company’s story ahead of the 1,000’s of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com

 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.